A federal policy shift has triggered a decline in patients receiving less-costly chemotherapy in physicians’ offices and a surge of those in more expensive hospital outpatient departments, according to a study released Monday. The trend, experts say, could have lasting effects on the quality of patient care, the existence of independent clinics and the future of Medicare.
Moran Co., a Washington-based healthcare research firm, confirmed that Medicare payments for fee-for-service hospital-based chemotherapy treatments have increased significantly while those for physicians’ offices have fallen.
According to the study, between 2005 and 2011 Medicare payments for chemotherapy administration in hospitals tripled to $300.9 million from $98.3 million, while payments for physician clinic chemotherapy administration dropped by 14.5 percent to $433.8 million from $507.5 million.
Read the full story here: http://bit.ly/14vD0YE
Source: Medill Reports Chicago
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
The Impact of Nurse Practitioner Attribution in Medicare Shared Savings ACOs
December 5th 2023Allowing nurse practitioners to serve as attribution-eligible providers for Medicare Shared Savings Program accountable care organizations leads to no change in hierarchical condition category risk scores and modest growth in attributed beneficiaries.
Read More